AbbVie (NYSE: ABBV), a Chicago-based biopharmaceutical company, announced a new $217 million investment to modernize its biologics manufacturing plant in Barceloneta, Puerto Rico. The upgrade will integrate advanced manufacturing technologies with artificial intelligence to support production of AbbVie’s current and next-generation medicines for immunology and neuroscience. Construction will begin this year, and the facilities are expected to be fully operational by 2030.
AbbVie plans to hire 100 people, including engineers, scientists, manufacturing operators and laboratory technicians. The company says it has committed more than $2.4 billion to U.S. manufacturing over the past 16 months and plans to create more than 1,400 jobs in North Carolina, Arizona, Massachusetts, Illinois and Puerto Rico. The project is part of AbbVie’s pledge to invest $100 billion in research and development and capital investments, including manufacturing, in the United States over the next decade.
Azita Saleki, AbbVie’s executive vice president and chief operating officer, said the company’s medicines are essential for patients and that its colleagues in Puerto Rico have long been fundamental to bringing treatments to patients. She said the investment reflects the company’s continued commitment to Puerto Rico and to strengthening its U.S. manufacturing network. AbbVie employs about 29,000 people in the United States, including more than 1,200 at its two Barceloneta plants.
In 2025 it announced the acquisition of Capstan Therapeutics for $2.1 billion, and since 2023 it has invested more than $20 billion in acquisitions after losing patent protection on Humira.